LGALS9 and Patent ductus arteriosus: Likewise, the vast majority of PDA TAMs robustly expressed the M2 marker CLEC7A (Dectin-1), which in concert with its ligand galectin 9 promotes strong immune suppression from macrophages that can be blocked to promote antitumor immunity in PDA (29).